oblimersen sodium Report issue

Biologics Nucleic acid Experimental
AACT ChEMBL Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

bcl-2 antisense oligodeoxynucleotide | dna, d(p-thio)(t-c-t-c-c-c-a-g-c-g-t-g-c-g-c-c-a-t) | dna, d(p-thio)(t-c-t-c-c-c-a-g-c-g-t-g-c-g-c-c-a-t) hepatadecasodium salt | g3139 | g 3139 | g-3139 oligonucleotide | g3139 oligonucleotide | genasense | oblimersen | oblimersen sodium

Organizations (23)

Research & Development (23)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (44)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (44)


 

Breast Neoplasms (Phase 1/Phase 2)

Breast Neoplasms, Male (Phase 1/Phase 2)

Burkitt Lymphoma (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Cardiotoxicity (Phase 1)

Colorectal Neoplasms (Phase 1/Phase 2)

Esophageal Neoplasms (Phase 1/Phase 2)

Gastrointestinal Stromal Tumors (Phase 2)

Head and Neck Neoplasms (Phase 1/Phase 2)

Hodgkin Disease (Phase 1)

Intestinal Neoplasms (Phase 1/Phase 2)

Intraocular Lymphoma (Phase 2)

Kidney Diseases (Phase 1)

Kidney Neoplasms (Phase 1/Phase 2)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 3)

Leukemia-Lymphoma, Adult T-Cell (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid, Acute (Phase 3)

Leukemia, Myeloid, Chronic-Phase (Phase 2)

Liver Diseases (Phase 2/Phase 3)

Liver Neoplasms (Phase 2)

Lung Neoplasms (Phase 2/Phase 3)

Lymphoma (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Large-Cell, Immunoblastic (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 1)

Lymphomatoid Granulomatosis (Phase 2)

Melanoma (Phase 3)

Multiple Myeloma (Phase 3)

Neoplasms (Phase 1/Phase 2)

Neuroendocrine Tumors (Phase 2)

Ovarian Neoplasms (Phase 1/Phase 2)

Prostatic Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Stomach Neoplasms (Phase 1/Phase 2)

Testicular Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 1/Phase 2)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 45
  • # of Trial Organizations: 23

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue